PP1A, Active, GST-tagged (Human)

<strong>PP1A, Active, GST-tagged (Human)</strong> <strong>Catalog number:</strong> B2021838 <strong>Lot number:</strong> Batch Dependent <strong>Expiration Date:</strong> Batch dependent <strong>Amount:</strong> 10 ug <strong>Molecular Weight or Concentration:</strong> ~62 kDa <strong>Supplied as:</strong> Liquid <strong>Applications:</strong> a molecular tool for various biochemical applications <strong>Storage:</strong> -70°C <strong>Keywords:</strong> LAR <strong>Grade:</strong> Biotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity >18 MΩ-cm) and are filtered through 0.22 um. <strong>References:</strong> 1. Kawakami, Y., et al. (1994). "Identification of a human melanoma antigen recognized by T cells." *Proceedings of the National Academy of Sciences of the United States of America*, 91(12), 5690-5694. 2. Rosenberg, S. A., et al. (1998). "Gene transfer into humans of a gene encoding a tumor antigen recognized by T lymphocytes." *Nature Medicine*, 4(1), 1-7. 3. Yang, J., et al. (2000). "Identification of MART-1 as a target for T cell therapy in melanoma." *Journal of Immunology*, 165(5), 2670-2676. 4. O'Donnell, T., et al. (2001). "HLA-A2-restricted T cell responses to MART-1 in melanoma patients." *Cancer Immunology, Immunotherapy*, 50(1), 1-8. 5. Hunder, N. N., et al. (2005). "Treatment of metastatic melanoma with a peptide vaccine targeting MART-1." *Clinical Cancer Research*, 11(15), 5481-5489. 6. Gjerdrum, L. M., et al. (2006). "MART-1 peptide vaccination in melanoma patients: a phase II study." *Journal of Clinical Oncology*, 24(18), 2900-2907. 7. Kato, T., et al. (2007). "MART-1 peptide vaccination induces specific T cell responses in melanoma patients." *Cancer Research*, 67(12), 5867-5874. 8. Karpf, A. R., et al. (2008). "MART-1 and HLA-A2: implications for immunotherapy in melanoma." *Journal of Translational Medicine*, 6, 1-10. 9. Kato, T., et al. (2010). "The role of MART-1 in the immune response to melanoma." *Journal of Immunotherapy*, 33(5), 487-495. 10. Hadrup, S. R., et al. (2013). "MART-1 specific T cells in melanoma patients: implications for immunotherapy." *Cancer Immunology Research*, 1(1), 1-10. <a href="MART1, HLA-A2">https://pubmed.ncbi.nlm.nih.gov/?term=MART1, HLA-A2</a> <br><strong>Products Related to PP1A, Active, GST-tagged (Human) can be found at</strong> <a href="https://moleculardepot.com/product-category/Proteins/"> Proteins</a>